Crinetics Pharmaceuticals Announces Upcoming Financial Results
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) is gearing up to share its financial results for the first quarter of 2025 on May 8, 2025, following the market's close. This announcement is a part of the company's continued commitment to transparency and stakeholder communication. In addition to the financial update, management will also host a conference call aimed at discussing the results and presenting a business update later that evening.
Details of the Conference Call
The conference call is scheduled for 4:30 p.m. ET. On this call, participants will have the opportunity to hear directly from the company's leadership about their financial performance and insights into future strategies and goals. Those interested in participating can dial in using the following numbers:
Dial-in Numbers
Domestic: 1-833-470-1428
International: 1-404-975-4839
Conference ID: CRNXQ1
Webcast Access
For those who prefer to participate online, a live webcast will also be available. The direct link to the webcast can be found on the Crinetics Pharmaceuticals website, where attendees are encouraged to join a few minutes ahead of time to ensure they are connected before the call begins. This webcast will also be archived for future access in the Investor Relations section of the company’s website, providing easy access for investors unable to attend the live discussion.
About Crinetics Pharmaceuticals
Founded with a mission to combat endocrine diseases and related tumors, Crinetics Pharmaceuticals is a clinical-stage pharmaceutical company that focuses on discovering and developing innovative therapies. The company has made significant strides with its lead candidate, paltusotine, recognized as the first investigational oral selective somatostatin receptor type 2 (SST2) nonpeptide agonist, aimed at treating acromegaly and carcinoid syndrome associated with neuroendocrine tumors.
In addition to paltusotine, Crinetics is advancing Atumelnant, which targets congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. All of Crinetics' drug candidates are small molecules that can be taken orally, developed through in-house discovery efforts. The company is continuously exploring new treatment options for various endocrine conditions, including hyperparathyroidism, polycystic kidney disease, Graves’ disease, and obesity, among others.
Investor Relations Contact
For inquiries regarding investments, Gayathri Diwakar is the Head of Investor Relations. She can be reached via email at gdiwakar@crinetics.com or by phone at (858) 345-6340.
Corporate Communications Contact
Natalie Badillo is the Head of Corporate Communications. Media inquiries can be directed to her email at nbadillo@crinetics.com or by calling (858) 345-6075.
Frequently Asked Questions
What does Crinetics Pharmaceuticals focus on?
Crinetics specializes in developing novel therapeutics for endocrine diseases and related tumors affecting patients.
When will Crinetics report their financial results?
The company is set to announce its first quarter 2025 financial results on May 8, 2025.
How can investors participate in the conference call?
Investors can join the call via provided domestic and international dial-in numbers or through a live webcast.
What is paltusotine?
Paltusotine is an investigational therapy developed by Crinetics, designed to treat conditions such as acromegaly and carcinoid syndrome.
Who can I contact for media inquiries?
Natalie Badillo, Head of Corporate Communications, can be contacted for media-related questions.